var data={"title":"Vitamin D3 (cholecalciferol): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin D3 (cholecalciferol): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5891?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-d3-cholecalciferol-drug-information\" class=\"drug drug_general\">see &quot;Vitamin D3 (cholecalciferol): Drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-d3-cholecalciferol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin D3 (cholecalciferol): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150802\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aqueous Vitamin D [OTC];</li>\n      <li>Bio-D-Mulsion Forte [OTC] [DSC];</li>\n      <li>Bio-D-Mulsion [OTC] [DSC];</li>\n      <li>BProtected Pedia D-Vite [OTC];</li>\n      <li>D-3-5 [OTC];</li>\n      <li>D-Vi-Sol [OTC];</li>\n      <li>D-Vita [OTC] [DSC];</li>\n      <li>D3-50 [OTC];</li>\n      <li>Decara [OTC];</li>\n      <li>Delta D3 [OTC];</li>\n      <li>Dialyvite Vitamin D 5000 [OTC];</li>\n      <li>Dialyvite Vitamin D3 Max [OTC];</li>\n      <li>Pronutrients Vitamin D3 [OTC];</li>\n      <li>Vitamin D3 Super Strength [OTC];</li>\n      <li>Vitamin D3 Ultra Potency [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150803\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>D-Vi-Sol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1005507\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin D Analog</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Fat Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442243\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adequate intake (AI):</b> Oral: 400 units/day (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency, prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AAP recommendations (Abrams 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;1.5 kg: 200 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;1.5 kg: 200 units/day; increase dose to 400 units/day when tolerating full enteral nutrition; maximum daily dose: 1,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Neonates &lt;1 kg: Oral: 150 to 400 units/kg/day (Greer 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term neonates: Breast-fed (fully or partially): Oral: 400 units/day beginning in the first few days of life; continue supplementation until infant is weaned to &ge;1,000 mL/day vitamin D-fortified formula (Golden 2014; Wagner 2008)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency, treatment:</b> Oral: <b>Note:</b> In addition to calcium and phosphorus supplementation: 2,000 units daily or 50,000 units once weekly for 6 weeks to achieve a serum 25(OH)D level &gt;20 ng/mL; followed by a maintenance dose of 400 to 1,000 units daily (Golden 2014; Holick 2011). <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (Golden 2014); some organizations suggest a serum 25(OH)D level &gt;30 ng/mL should be used for all patients (Holick 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1005525\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vitamin-d3-cholecalciferol-drug-information\" class=\"drug drug_general\">see &quot;Vitamin D3 (cholecalciferol): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake (AI):</b> Oral: Infants: 400 units/day (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended Daily Allowance (RDA):</b> Oral: Children and Adolescents: 600 units/day (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D deficiency, prevention:</b> (Wagner 2008): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Breast-fed infants (fully or partially): Oral: 400 units/day beginning in the first few days of life. Continue supplementation until infant is weaned to &ge;1,000 mL/day or 1 qt/day of vitamin D-fortified formula or whole milk (after 12 months of age) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Formula-fed infants ingesting &lt;1,000 mL of vitamin D-fortified formula: Oral: 400 units/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents without adequate intake:  Oral: 400 units/day. <b>Note:</b> Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications): Higher doses may be required; use laboratory testing [25(OH)D, PTH, bone mineral status] to evaluate  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D deficiency, treatment:</b> Oral: <b>Note:</b> In addition to calcium and phosphorus supplementation (Holick 2011; Golden 2014): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Oral: 2,000 units daily or 50,000 units once weekly for 6 weeks to achieve a serum 25(OH)D level &gt;20 ng/mL; followed by a maintenance dose of 400 to 1,000 units daily. <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (Golden 2014); some organizations suggest a serum 25(OH)D level &gt;30 ng/mL should be used for all patients (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: Oral: 2,000 units daily  or 50,000 units once weekly for 6 to 8 weeks to achieve  serum 25(OH)D level &gt; 20 ng/mL; followed by a maintenance dose of 600 to 1,000 units daily. <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (Golden 2014); some organizations suggest a serum 25(OH)D level &gt;30 ng/mL should be used for all patients (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications, glucocorticoids, HIV medications and antifungals such as ketoconazole, obesity): Higher doses (2 to 3 times higher) may be required; doses of at least 6,000 to 10,000 units daily until serum 25(OH)D level &gt;30 ng/mL, followed by a maintenance dose of 3,000 to 6,000 units daily have been suggested (Holick 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If poor compliance, single high-dose administration (100,000 to 600,000 units over 1 to 5 days) followed by maintenance dosing; intermittently repeating (usually every 3 months) may be needed if poor compliance continues with maintenance dosing (Misra 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D insufficiency or deficiency associated with CKD (stages 2-5, 5D), treatment; serum 25 hydroxyvitamin D [25(OH)D] level &le;30 ng/mL</b> (KDOQI Guidelines 2009): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum 25(OH)D level 16 to 30 ng/mL: Infants, Children, and Adolescents: 2,000 units/day for 3 months or 50,000 units every month for 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum 25(OH)D level 5 to 15 ng/mL: Infants, Children, and Adolescents: 4,000 units/day for 12 weeks or 50,000 units every other week for 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum 25(OH)D level &lt;5 ng/mL: Infants, Children, and Adolescents: 8,000 units/day for 4 weeks then 4,000 units/day for 2 months for total therapy of 3 months or 50,000 units/week for 4 weeks followed by 50,000 units 2 times/month for a total therapy of 3 months </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose [once repletion accomplished; serum 25(OH)D level &gt;30 ng/mL]: Infants, Children, and Adolescents: 200 to 1,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D Deficiency in cystic fibrosis, prevention and treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CF guidelines (Tangricha [CF Foundation] 2012): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Recommended inital daily intake to maintain serum 25(OH)D level &ge;30 ng/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants: Oral: 400  to 500 units/day </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &le;10 years: Oral: 800 to 1,000 units/day </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;10 years and Adolescents: Oral: 800 to 2,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosing adjustment for serum 25(OH)D level between 20 to 30 ng/mL and patient adherence established (Step 1 increase): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants: Oral: 800 to 1,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &le;10 years: Oral: 1,600 to 3,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;10 years and Adolescents: Oral: 1,600 to 6,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosing adjustment for serum 25(OH)D level &lt;20 ng/mL or persistently  between 20 to 30 ng/mL and patient adherence established (Step 2 increase):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants: Increase up to a maximum 2,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &le;10 years: Increase to a maximum of 4,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;10 years and Adolescents: Increase to a maximum of 10,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (Hall 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose: Serum 25(OH)D level &le;30 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants: Oral: 8,000 units/<b>week</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents: Oral: 800 units/day </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Medium-dose regimen: Serum 25(OH)D level remains &le;30 ng/mL and patient compliance established</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &lt;5 years: Oral: 12,000 units/week for 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;5 years and Adolescents: Oral: 50,000 units/week for 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High-dose regimen: Repeat 25(OH)D level remains &le;30 ng/mL and patient compliance established</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &lt;5 years: Oral: 12,000 units twice weekly for 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;5 years and Adolescents: Oral: 50,000 units twice weekly for 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended Daily Allowance (RDA)</b> (IOM 2011): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults 19 to 70 years: 600 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Female: Pregnancy/lactating: 600 units/day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoporosis prevention and treatment:</b> Oral: 800 to 1,000 units/day (NOF guidelines 2014) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D deficiency treatment:</b> Oral: 6,000 units daily or 50,000 units once weekly for 8 weeks to achieve serum 25(OH)D level &gt;30 ng/mL, followed by a maintenance dose of 1,500 to 2,000 units daily (Holick 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150796\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D3-50: 50,000 units [dairy free, egg free, fish derivative free, gluten free, kosher certified, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decara: 10,000 units [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake, gelatin (bovine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decara: 25,000 units [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decara: 50,000 units [contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dialyvite Vitamin D 5000: 5000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pronutrients Vitamin D3: 1000 units [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10,000 units, 50,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D-3-5: 5000 units [dairy free, dye free, egg free, gluten free, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D3-50: 50,000 units [dairy free, egg free, fish derivative free, gluten free, kosher certified, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2000 units, 5000 units, 10,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aqueous Vitamin D: 400 units/mL (50 mL) [gluten free, lactose free, sugar free; contains methylparaben, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bio-D-Mulsion: 400 units/0.03 mL (30 mL [DSC]) [contains sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bio-D-Mulsion Forte: 2000 units/0.03 mL (30 mL [DSC]) [contains sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BProtected Pedia D-Vite: 400 units/mL (50 mL) [alcohol free, sugar free; contains polysorbate 80, propylene glycol, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D-Vi-Sol: 400 units/mL (50 mL) [gluten free, lactose free, sugar free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D-Vita: 400 units/mL (50 mL [DSC]) [alcohol free, gluten free, lactose free, sugar free; contains polysorbate 80, propylene glycol, sodium benzoate; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units/mL (50 mL, 52.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5000 units/mL (52.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delta D3: 400 units [gelatin free, gluten free, lactose free, no artificial color(s), no artificial flavor(s), starch free, sugar free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dialyvite Vitamin D3 Max: 50,000 units [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vitamin D3 Super Strength: 2000 units [gluten free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vitamin D3 Ultra Potency: 50,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units, 1000 units, 2000 units, 3000 units, 5000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units, 1000 units, 2000 units, 5000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150785\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10135969\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to meals; for oral liquid, use accompanying dropper for dosage measurements </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25188822\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1005508\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention and treatment of vitamin D deficiency and/or rickets; dietary supplement (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10303065\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cholecalciferol may be confused with alfacalcidol, ergocalciferol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 international units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 international units per dose.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150830\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">No adverse reactions listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150799\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: Replesta products only: When used for self-medication, do not use if you have hypercalcemia, primary hyperparathyroidism, sarcoidosis, hypervitaminosis D, Williams syndrome, or are pregnant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for vitamin D is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283820\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin D toxicity: May occur with excessive doses; symptoms may include nausea, vomiting, loss of appetite, constipation, dehydration, fatigue, irritability, confusion, weakness and/or weight loss. Effects of vitamin D can last &ge;2 months after therapy is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: May be at greater risk of vitamin D toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: May be at greater risk of vitamin D toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse  (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Adults with a BMI &gt;30 kg/m<sup>2</sup> are at high risk for vitamin D deficiency due to storage of vitamin D in adipose tissue. Doses higher than the RDA may be required, but must be carefully monitored to avoid toxicity (Holick 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26522859\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150824\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150791\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13086&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13861968\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">The cholecalciferol metabolite, 25(OH)D, crosses the placenta; maternal serum concentrations correlate with fetal concentrations at birth (Misra 2008; Wagner 2008). Vitamin D requirements are the same in pregnant and nonpregnant females (IOM 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vitamin D deficiency in a pregnant woman may lead to a vitamin D deficiency in the neonate (Misra 2008; Wagner 2008). Serum 25(OH)D concentrations should be measured in pregnant women considered to be at increased risk of deficiency (ACOG 2011). The amount of vitamin D contained in prenatal vitamins may not be adequate to treat a deficiency during pregnancy; although larger doses may be needed, current guidelines recommend a total of 1,000 to 2,000 units/day until more safety data is available (ACOG 2011; Holick 2011). In women not at risk for deficiency, doses larger than the RDA should be avoided during pregnancy (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10135970\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Children at increased risk of vitamin D deficiency (chronic fat malabsorption, chronic antiseizure medication use) require serum 25(OH)D, PTH, and bone-mineral status to evaluate. If vitamin D supplement is required, then 25(OH)D levels should be repeated at 3-month intervals until normal. PTH and bone mineral-status should be monitored every 6 months until normal. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chronic kidney disease: Monitor serum 25(OH)D, corrected total calcium and phosphorus levels 1 month following initiation of therapy, every 3 months during therapy and with any Vitamin D dose change; alkaline phosphatase, BUN</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10135971\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Vitamin D status may be determined by serum 25(OH)D levels (Misra 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe deficiency: &le;5 ng/mL (12.5 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deficiency: 15 ng/mL (37.5 nmol/L)     </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insufficiency: 15 to 20 ng/mL (37.5 to 50 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sufficiency: 20 to 100 ng/mL (50 to 250 nmol/L)*</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excess: &gt;100 ng/mL (250 nmol/L)**</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intoxication: 150 ng/mL (375 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">*Based on adult data a level of &gt;32 ng/mL (80 nmol/L) is desirable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">**Arbitrary designation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Target  serum 25(OH)D: &gt;30 ng/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283822\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cholecalciferol (vitamin D<sub>3</sub>) is a provitamin. The active metabolite, 1,25-dihydroxyvitamin D (calcitriol), stimulates calcium and phosphate absorption from the small intestine, promotes secretion of calcium from bone to blood; promotes renal tubule phosphate resorption (IOM 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595885\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;\">Absorption: Absorbed in the small intestine; fat soluble; requires bile (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Inactive until hydroxylated hepatically to 25-hydroxyvitamin D [25(OH)D; calcifediol] then renally to the active metabolite 1,25-dihydroxyvitamin D (calcitriol) (IOM 2011)</p>\n    <p style=\"text-indent:0em;\">Half-life, circulating: 25(OH)D: 2 to 3 weeks; 1,25-dihydroxyvitamin D: ~4 hours (Holick 2011)</p>\n    <p style=\"text-indent:0em;\">Excretion: Feces (IOM 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10135975\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">1 mcg cholecalciferol provides 40 units of vitamin D activity</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Biological potency may be greater with cholecalciferol (vitamin D<sub>3</sub>) compared to ergocalciferol (vitamin D<sub>2</sub>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Chronic kidney disease (CKD) (KDIGO, 2013; KDOQI, 2002): Children &ge;2 years, Adolescents, and Adults: GFR &lt;60 mL/minute/1.73 m<sup>2</sup> or kidney damage for &ge;3 months; stages of CKD are described below: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 1: Kidney damage with normal or increased GFR; GFR &gt;90 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 2: Kidney damage with mild decrease in GFR; GFR 60 to 89 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 3: Moderate decrease in GFR; GFR 30 to 59 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 4: Severe decrease in GFR; GFR 15 to 29 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 5: Kidney failure; GFR &lt;15 mL/minute/1.73 m<sup>2</sup> or dialysis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323065\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (D3-50 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000 unit (100): $20.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Decara Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 unit (50): $40.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000 unit (30): $57.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000 unit (50): $58.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dialyvite Vitamin D 5000 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 unit (90): $11.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Pronutrients Vitamin D3 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (120): $8.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (BProtected Pedia D-Vite Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 units/mL (50 mL): $8.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (D-Vi-Sol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 units/mL (50 mL): $8.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dialyvite Vitamin D3 Max Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000 unit (12): $12.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Vitamin D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (100): $2.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150800\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adalben (ES);</li>\n      <li>Arachitol (IN);</li>\n      <li>Aviticol (GB);</li>\n      <li>Baby D Drops (SG);</li>\n      <li>D Drops (SG);</li>\n      <li>D-Cure (BE, LU);</li>\n      <li>D3 Capsules (AU);</li>\n      <li>D3 Drops (AU);</li>\n      <li>D3 Drops Forte (AU);</li>\n      <li>D4U (LK);</li>\n      <li>Deetipat (FI);</li>\n      <li>Dekristol 400 (DE);</li>\n      <li>Dekristolmin (AT);</li>\n      <li>Deltius (ES);</li>\n      <li>Desunin (GB);</li>\n      <li>Devaron (NL);</li>\n      <li>Devitre (SE);</li>\n      <li>Duvit D3 (IT);</li>\n      <li>Fultium-D3 (GB);</li>\n      <li>Iper D3 (IT);</li>\n      <li>Laevovit (HU);</li>\n      <li>Laevovit D3 (AT);</li>\n      <li>Ostelavit (PL);</li>\n      <li>Plivit D3 (HR);</li>\n      <li>Teorol (ID);</li>\n      <li>Tridelta (IT);</li>\n      <li>Uvedose (FR, LU);</li>\n      <li>Vi-De 3 (CH);</li>\n      <li>Vigantol (CZ, HU, LU, PL, PT);</li>\n      <li>Vigantoletten (LU, PL);</li>\n      <li>Vitamin D3 (HU);</li>\n      <li>Vitamin D3 Fresenius (HU);</li>\n      <li>Vitamin D3 Streuli (CH);</li>\n      <li>Vitamine D3 BON (FR);</li>\n      <li>Vitaminum D3 (PL);</li>\n      <li>Vitamon D3 (BE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abrams SA, Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. <i>Pediatrics</i>. 2013;131(5):e1676-1683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/23629620 /pubmed\" target=\"_blank\" id=\"23629620 \">23629620 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borowitz D, Baker RD, and Stallings V, &quot;Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2002, 35(3):246-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/12352509/pubmed\" target=\"_blank\" id=\"12352509\">12352509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golden NH, Abrams SA, Committee on Nutrition. Optimizing bone health in children and adolescents. <i>Pediatrics</i>. 2014;134(4):e1229-1243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/25266429 /pubmed\" target=\"_blank\" id=\"25266429 \">25266429 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gordon CM, Williams AL, Feldman HA, et al, &ldquo;Treatment of Hypovitaminosis D in Infants and Toddlers,&rdquo; <i>J Clin Endocrinol Metab</i>, 2008, 93:2716-21.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greer FR, &quot;Vitamin Metabolism and Requirements in the Micropremie,&quot; <i>Clin Perinatol</i>, 2000, 27(1):95-118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/10690566/pubmed\" target=\"_blank\" id=\"10690566\">10690566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall WB, Sparks AA, and Aris RM, &quot;Vitamin D Deficiency in Cystic Fibrosis,&quot; <i>Int J Endocrinol</i>, 2010, 218691.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/20148079/pubmed\" target=\"_blank\" id=\"20148079\">20148079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2011;96(7):1911-1930.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/21646368 /pubmed\" target=\"_blank\" id=\"21646368 \">21646368 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollis BW and Wagner CL, &quot;Vitamin D Requirements During Lactation: High-Dose Maternal Supplementation as Therapy to Prevent Hypovitaminosis D for Both the Mother and the Nursing Infant,&quot; <i>Am J Clin Nutr</i>, 2004, 80(6 Suppl):1752S-8S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/15585800/pubmed\" target=\"_blank\" id=\"15585800\">15585800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. Washington, DC: The National Academies Press; 2011. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI Work Group, &quot;KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update. Executive Summary,&quot; <i>Am J Kidney Dis</i>, 2009, 53(3 Suppl 2):S11-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/19231749/pubmed\" target=\"_blank\" id=\"19231749\">19231749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3:1-150. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misra M, Pacaud D, Petryk A, et al, &quot;Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations,&quot; <i>Pediatrics</i>, 2008, 122(2):398-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/18676559/pubmed\" target=\"_blank\" id=\"18676559\">18676559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Osteoporosis Foundation (NOF). Clinician&rsquo;s guide to prevention and treatment of osteoporosis. Washington, DC, 2014. Available at http://nof.org/hcp/resources/913</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saadi HF, Dawodu A, Afandi B, et al, &quot;Effect of Combined Maternal and Infant Vitamin D Supplementation on Vitamin D Status of Exclusively Breastfed Infants,&quot; <i>Matern Child Nutr</i>, 2009, 5(1):25-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/19161542/pubmed\" target=\"_blank\" id=\"19161542\">19161542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tangpricha V, Kelly A, Stephenson A, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. <i>J Clin Endocrinol Metab</i>. 2012;97(4):1082-1093.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/22399505 /pubmed\" target=\"_blank\" id=\"22399505 \">22399505 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor SN, Wagner CL, and Hollis BW, &quot;Vitamin D Supplementation During Lactation to Support Infant and Mother,&quot; <i>J Am Coll Nutr</i>, 2008, 27(6):690-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/19155428/pubmed\" target=\"_blank\" id=\"19155428\">19155428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, et al, &quot;Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents,&quot; <i>Pediatrics</i>, 2008, 122(5):1142-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-pediatric-drug-information/abstract-text/18977996/pubmed\" target=\"_blank\" id=\"18977996\">18977996</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13086 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F150802\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F150803\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1005507\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442243\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1005525\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F150796\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F150785\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10135969\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25188822\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1005508\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10303065\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F150830\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F150799\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46283820\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26522859\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F150824\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F150791\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13861968\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10135970\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F10135971\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46283822\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F595885\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10135975\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323065\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F150800\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13086|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-d3-cholecalciferol-drug-information\" class=\"drug drug_general\">Vitamin D3 (cholecalciferol): Drug information</a></li><li><a href=\"topic.htm?path=vitamin-d3-cholecalciferol-patient-drug-information\" class=\"drug drug_patient\">Vitamin D3 (cholecalciferol): Patient drug information</a></li></ul></div></div>","javascript":null}